Voprosy onkologii
-
Clinical Trial Controlled Clinical Trial
[Criteria for suppressive dosage of thyroxine administered in thyroid cancer].
The investigation was concerned with thyroxine therapy for suppression of thyrotrophin synthesis in 1,033 out of 1,544 (66.9%) patients treated for papillary thyroid cancer (hemithyroidectomy--429, thyroidectomy--1,115; 484 of the latter group received radioiodinetherapy postoperatively). Thyroxine 2-5.2 mg/body mass unit was administered for 1-10 yrs (average--4. yrs). Effective daily dose depended on extent of surgery: higher dosage was required after thyroidectomy than hemithyroidectomy, and it was significantly higher after radioiodinetherapy. ⋯ Also, an inverse relationship was established between suppressive dose and age. Male patients appeared to require more thyroxine per day than women. Suppressive dosage of thyroxine with regard to age, sex and treatment modality is suggested.
-
Comparative Study
[Clinico-radiological assessment of chemotherapy for osteosarcoma received prior to surgery].
A clinico-radiological evaluation of chemotherapy received by 20 patients with osteosarcoma at the Institute's Clinic (1999-2003) was conducted. Morhological confirmation of the findings on course dynamics agreed upon by clinicians and roentgenologists was obtained in 78%. X-ray examinations provided more information. The clinico-radiological evidence on tumor regression failed morphological test in one-third of cases.
-
While general cervical carcinoma morbidity is on the decline in most of the surveyed Russian Federation areas characterized by varying levels of industrial pollution, the heavily industrialized region of Salavat revealed a different tendency. Its level was 1.6 times (p<0.05) those in other areas. That was due to the morbidity of women aged 40-69 and even 20-29 and 30-39 years.